FacultyFaculty/Author Profile

Paul D. Rubin

Debevoise & Plimpton LLP

Washington, DC, USA


Paul D. Rubin is a corporate partner based in the Washington, D.C. office and a member of the Healthcare Group. His practice focuses on FDA/FTC regulatory matters. He is noted as a recognized practitioner for Regulatory Healthcare by Chambers USA (2018) and is an LMG Life Sciences: “Life Sciences Star” (2013–2017).

Mr. Rubin represents FDA-regulated drug, device and consumer product companies on a wide range of issues, ranging from strategic regulatory counseling to complex compliance and enforcement matters. He also routinely conducts regulatory due diligence for private equity funds and strategic acquirers in corporate transactions.

In addition to his FDA practice, Mr. Rubin also has substantial experience helping clients navigate complex advertising and promotion-related issues, including FTC investigations, negotiating FTC settlements/consent decrees, disputes before the National Advertising Division of the Better Business Bureau (NAD) and advertising lawsuits under Section 43(a) of the Lanham Act. Mr. Rubin also has considerable experience advising consumer product companies on CPSC-related compliance, including Section 15(b) submissions and “Fast Track Recalls.”

Mr. Rubin is a contributing author to the Health Care Mergers and Acquisitions Answer Book (Practising Law Institute, 2017) and the co-author of various articles, including “A Look at Recent Efforts to Contain Health Care Costs,” Law360 (January, 2018) and “How Tax Reform Could Impact the Health Care Industry,” Law360 (November, 2017).

Mr. Rubin joined Debevoise in 2017. He earned his J.D. cum laude from the University of Pennsylvania Law School in 1992. He received a B.S. magna cum laude from the University of Pennsylvania Wharton School of Business in 1989.

Paul D. Rubin is associated with the following items:
Answer Book Chapters  Answer Book Chapters Manufacturing and Distribution Requirements - Health Care Mergers and Acquisitions Answer Book (2018 Edition), Wednesday, July 25, 2018
FDA Investigations and Enforcement - Health Care Mergers and Acquisitions Answer Book (2018 Edition), Wednesday, July 25, 2018
Patent Extensions and Market Exclusivities - Health Care Mergers and Acquisitions Answer Book (2018 Edition), Wednesday, July 25, 2018
Compliance with Import and Export Requirements - Health Care Mergers and Acquisitions Answer Book (2018 Edition), Wednesday, July 25, 2018
Compliance with DEA Controlled Substance Requirements - Health Care Mergers and Acquisitions Answer Book (2018 Edition), Wednesday, July 25, 2018
Product Development and Marketing - Health Care Mergers and Acquisitions Answer Book (2018 Edition), Wednesday, July 25, 2018
Live Webcast Briefing  Live Webcast Briefing SEC/FDA Nexus: Best Practices for Publicly Traded Life Sciences Companies, Wednesday, February 20, 2019
Share
Email

  • FOLLOW PLI:
  • twitter
  • LinkedIn
  • YouTube
  • RSS

All Contents Copyright © 1996-2019 Practising Law Institute. Continuing Legal Education since 1933.

© 2019 PLI PRACTISING LAW INSTITUTE. All rights reserved. The PLI logo is a service mark of PLI.